Research Article

Controlled clinical trial of L-dopa and nafoxidine in advanced breast cancer: an E.O.R.T.C. study.

Br Med J 1975; 2 doi: https://doi.org/10.1136/bmj.2.5973.714 (Published 28 June 1975) Cite this as: Br Med J 1975;2:714
  1. E Engelsman,
  2. J C Heuson,
  3. J Blonk Van Der Wijst,
  4. A Drochmans,
  5. H Maass,
  6. F Cheix,
  7. L G Sobrinho,
  8. H Nowakowski

    Abstract

    L-Dopa lowers plasma prolactin levels, and there have been reports that patients with advanced breast cancer have been successfully treated with L-dopa. To test the potential value of L-dopa in this disease a randomized clinical trial of L-dopa and nafoxidine (as the reference compound) was conducted in postmenopausal women with advanced breast cancer. Objective remissions were obtained in sever out of 36 patients (19%) treated with nafoxidine but in none out of 40 patients treated with L-dopa. L-Dopa in the dose schedule used seems to be ineffective in advanced breast cancer.